According to the contract, Lion Biotechnologies has received license from Moffitt for the rights to develop and commercialise new technologies to improve tumour infiltrating lymphocytes production from melanoma. The company stated that the license is based on two provisional patent applications, filed under 'Compositions and Methods for Improving Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.'
Lion chief scientific officer Laszlo Radvanyi said, 'This licensing agreement with Moffitt gives us access to technologies that may allow us to enhance TIL production from these tumors, thereby unlocking the potential of TILs to treat, and possibly cure, certain cancers beyond melanoma.'
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia